Buy Teradyne

By Joe Duarte • February 3, 2017

I am issuing a buy recommendation for Teradyne (NYSE: TER), a leader in electronic manufacturing equipment testing equipment. The stock is starting to accelerate to the upside on the bullish dynamic that is starting to spread in the semiconductor sector. The company recently beat its earnings expectations for the fifth quarter in a row, raised its dividend and updated its guidance for its upcoming quarter. Buy Teradyne up to $30.

I will have more in this Monday’s edition of Breakthrough Tech Weekly.

I have a position in Teradyne.

Stock Talk

Comments Oldest First

Comments Guidelines

Rick

02/03/17 ‐ 2:24pm ET February 3, 2017 at 2:24pm ET

Bought the Jul 2017 $28 calls at $2.55.

Joe Duarte

02/03/17 ‐ 2:41pm ET February 3, 2017 at 2:41pm ET

There is indeed a bid under the semis at the moment.

Edward Getchell

05/01/17 ‐ 12:44pm ET May 1, 2017 at 12:44pm ET

May 1, 2017

Teradyne has been doing very well and is well past its $30 limit. Do you think the limit should be raised?

Thanks,

Igor Greenwald

05/02/17 ‐ 1:26pm ET May 2, 2017 at 1:26pm ET

I’ll have more on Teradyne later today and yes, I do ;-).

Add New Comments

You must be logged in to post to Stock Talk OR create an account

About The Author

Joe Duarte

Bio | Archive

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.